Comparision of the efficacy of pharmacotherapy and combination of pharmacotherapy with transdiagnostic cognitive-behavior therapy on anxiety and depression symptoms in patients with emotional disorders

Phase 3

• Conditions: Anxiety disorders and complex depression.; Anxiety disorders and complex depression; F41.3

• Registration Number: IRCT20181019041385N1
• Lead Sponsor: The university of kurdestan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 February 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

Anxiety Disorder and Comorbid Depression (According to Psychiatrist)
Sanandaj resident
No history of substance abuse
The desire to participate and not receive any therapeutic intervention, including psychological and medication, at least in the last year

Exclusion Criteria

Has personality disorders
A history of suicide
illiterate

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Anxiety. Timepoint: pre test, post test and follow up(one month after treatment). Method of measurement: Beck Anxiety Inventory.;Depression. Timepoint: pre test, post test and follow up(one month after treatment). Method of measurement: Beck Depression Inventory.

Secondary Outcome Measures

Name	Time	Method
Emotional regulaition. Timepoint: Before and after 8 sessions of treatment. Method of measurement: Use the emotion regulation difficulty questionnaire.;Negative repetitive thoughts. Timepoint: Before and after 8 sessions of treatment. Method of measurement: Using Negative repetitive Thought Questionnaire.;Intolerance of Uncertainly. Timepoint: Before and after 8 sessions of treatment. Method of measurement: Use of uncertainty intolerance questionnaire.;Anxiety Sensitivity. Timepoint: Before and after 8 sessions of treatment. Method of measurement: Anxiety Sensitivity Questionnaire.;Experiential Avoidance. Timepoint: Before and after 8 sessions of treatment. Method of measurement: Experiential Avoidance Questionnaire.